literature

HIV mutation literature information.

Correlation of HIV-1 drug resistant mutations and virologic failure.

PMID: 34584606 2021 The Pan African medical journal

Introduction: These mutations included M184V, K65R,D67N,K70R,K219Q,Q151M, T215F, M41L, T69N, V75M, M41L, T69N, V75M, D67G, V75M, M184I, T215N, M41LM, T215N, K219N,210W, T215Y as NRT

Table: M230L

HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.

PMID: 34762770 2021 Journal of the International AIDS Society

Table: M230I/L

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.

PMID: 34622871 2021 Medicine

Result: K103N/S 56 (21.0%), G190S/A 39 (14.6%), Y181C/I 29 (10.9%), V108I 13 (4.9%), P225H 12 (4.5%), Y188L 7 (2.6%), M230L 7 (2.6%), L100I 5 (1.9%), V106 M 5 (1.9%), and K101P 2 (0.7%) were the mutations conferring resistance to NNRTIs.

HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.

PMID: 34377002 2021 Infection and drug resistance

Table: M230L

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.

PMID: 32041622 2020 AIDS research and therapy

Table: M230L

HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.

PMID: 32280691 2020 BioMed research international

Result: K103N (37.55%, 92/245) was the most frequent mutation, followed by G190A/E/K/Q/S/V (28.57%, 70/245), V179I/D/E/T (27.76%, 68/245), V106A/I/M (26.12%, 64/245), Y181C/V (18.78%, 46/245), K101E/H/P (14.69%, 36/245), Y188C/H/L (5.71%, 14/245), L100I (4.08%, 10/245), and M230L (4.08%, 10/245).

Discussion: The L100I and M230L mutations (4.08%) had low incidence and intermediate or high resistance to RPV and ETR but no resistance to the first-line drugs EFV and NVP.

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.

PMID: 32265875 2020 Frontiers in microbiology

Result: H221Y and M230L occurred in one (1%) patient each; both these patients were receiving AZT plus 3TC.

Table: M230L

Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.

PMID: 32183889 2020 Virology journal

Table: M230L

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.

PMID: 32180823 2020 Drugs in context

Introduction: Finally, substitutions that disrupt the NNRTI-binding pocket, such as Y188L and M230L, confer pan-resistance against all NNRTIs.

Introduction: Other single substitutions including G190E/S, V106A, Y188L, and M230L reduced DOR susceptibility >10-fold.

Introduction: The G190S, Y188L, and M230L substitutions confer >95-fold resistance.

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

PMID: 31976534 2020 The Journal of antimicrobial chemotherapy

Abstract: RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus 9.2%; Y188L, 1.2% versus 2.6%; G190S, 0.3% versus 2.1%; F227C/L/V, 0.5% versus 1.8%; M230I/L, 2.8% versus 0%; L234I, 0.1% versus 0.5%; K103N + Y181C, 3.9% versus 3.9%; K103N + P225H, 2.9% versus 4.7%; and K103N + L100I, 1.7% versus 3.9%, with a significantly higher proportion of these mutations in the

Browser Board

Co-occurred Entities

Filtrator